RACR-induced cytotoxic innate lymphocytes permit the expansion and differentiation of iPSCs with fewer limitations, leading to a more cost-effective manufacturing process
SEATTLE, May 4, 2022 鈥� 密桃视频, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo for patients with solid and hematologic malignancies, announced today that it will have an oral presentation at the International Society for Cell and Gene Therapy (ISCT) Annual Meeting 2022, to be held May 4-7, 2022 in San Francisco, California.
On Friday, May 6th, Dave Vereide, Ph.D., Senior Scientist at 密桃视频, will give an oral presentation titled 鈥淎 synthetic cytokine receptor platform for producing cytotoxic innate lymphocytes as 鈥榦ff-the-shelf鈥� cancer therapeutics.鈥� The presentation will highlight 密桃视频鈥檚 rapamycin-activated cytokine receptor (RACR) platform which seeks to address current challenges in the cellular therapy space. Current approaches for differentiating induced pluripotent stem cells (iPSCs) into therapeutic immune cell types often requires expensive exogenous gamma-chain cytokines for expansion and survival, and often, the presence of feeder cells. The RACR platform permits the production of immune effector cells, termed RACR-induced cytotoxic innate lymphocytes (iCILs), in the absence of exogenous cytokines and feeder cells by genetically modifying iPSC-derived progenitor cells to express the RACR synthetic cytokine receptor. A synthetic small molecule ligand then binds RACR to drive the differentiation and expansion of the iCILs. RACR technology can be employed in both a manufacturing setting to generate iCILs and in vivo to enable the selective expansion and survival of iCILs.
鈥渋PSCs are an excellent source of renewable, modifiable, and scalable material for cell therapy manufacturing, yet several limitations exist with the current manufacturing processes for differentiating iPSCs into therapeutic cell types, including the need for exogenous growth factors and feeder cells.鈥� said Andy Scharenberg, M.D., co-founder and Chief Executive Officer of 密桃视频. 鈥淎t 密桃视频 we are excited about our RACR-iCIL iPSC platform and its capacity to generate immune effector cells in the absence of these limitations. Due to the selective growth advantage provided by our RACR platform, a highly pure iCIL population can be produced during manufacturing. We are evaluating iCILs in pre-clinical studies to assess their in vivo anti-tumor activity, and are optimistic about their potential for development as 鈥渙ff-the-shelf鈥� cell therapies for diverse hematologic malignancies and solid tumors.鈥�
Presentation details:
Presentation Title: A synthetic cytokine receptor platform for producing cytotoxic innate lymphocytes as 鈥榦ff-the-shelf鈥� cancer therapeutics
Presenting Author: Dave Vereide, Ph.D., Senior Scientist at 密桃视频
Abstract Number: 44
Oral Presentation Session: Gene Editing/Gene Therapies
Oral Presentation Date, Time: Friday May 6, 2022; 4:45-5:45 p.m. PT
Poster Presentation Session: Poster Networking Reception 2
Poster Presentation Date, Time: Thursday May 5, 2022; 5:45-7:15 p.m. PT
About 密桃视频, Inc.
密桃视频, Inc., is developing treatments for solid tumors and hematologic cancers that reprogram the patient鈥檚 immune system in vivo. Our technology platforms are designed to work synergistically as part of a therapeutic regimen that can be delivered to any patient, with any tumor, at any time. Based on pioneering work performed at Seattle Children鈥檚 Research Institute and Purdue University, 密桃视频鈥檚 approach is powered by novel cellular immunotherapy technologies including the VivoVec in vivo delivery platform, the RACR/CAR in vivo cell expansion/control platform, and the TumorTag targeting platform. 密桃视频 believes its approach can broaden access to advanced immunotherapies to give more patients the hope of lasting remission. To learn more, visit鈥痟ttp://umoja-biopharma.com/.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about 密桃视频, Inc. (the 鈥淐ompany,鈥� 鈥渨e,鈥� 鈥渦s,鈥� or 鈥渙ur鈥�). The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Company鈥檚 current and future research and development programs, preclinical and clinical trials, as well as the economic, market and social disruptions due to the ongoing COVID-19 public health crisis. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.
Media Contact:
Darren Opland, Ph.D.
LifeSci Communications
darren@lifescicomms.com